Obecabtagene Autoleucel

CHEMBL5095440 Phase 4 Onaylandı Gene

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

A CAR-T cell therapy in which a patient's own T cells are engineered to express a chimeric antigen receptor targeting CD19, used to treat relapsed or refractory B-cell acute lymphoblastic leukemia and other B-cell malignancies. The modified cells are infused back into the patient, where they recognize and destroy CD19-positive cancer cells.

Terapötik Alanlar

Systemic Lupus Erythematosus Multiple Sclerosis Lymphoma Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A CAR-T cell therapy in which a patient's own T cells are engineered to express a chimeric antigen receptor targeting CD19, used to treat relapsed or refractory B-cell acute lymphoblastic leukemia and other B-cell malignancies. The modified cells are infused back into the patient, where they recognize and destroy CD19-positive cancer cells.

Yes, Obecabtagene Autoleucel is an approved drug. It has reached clinical phase 4. It is classified as a Gene.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5095440. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Obecabtagene Autoleucel PillFYI'da

Hızlı Veriler

Eş Anlamlılar: 1

Dış Bağlantılar

ChEMBL CHEMBL5095440

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.